Prostate cancer is now the most common malignancy and the second leading cause of cancer death in North American males. Androgen antagonists offer a potentially useful treatment for androgen-mediated diseases, such as: prostate cancer, hirsutism, acne, seborrhea, androgenic alopecia and benign prostatic hyperplasia. 1 Although surgery presently represents the usual treatment for prostate cancer, there are several other alternative modalities currently available for the treatment of these androgene-dependent affilictions. 2 At the present time, the most common therapy for the treatment of prostate cancer and benign prostatic hyperplasia is blockage of the androgen receptor by androgen antagonists or inhibition of the conversion of testosterone to the more active androgen, dihydrotestosterone by the enzyme 5a-reductase. 3 In this paper we describe the synthesis and X-ray structure determination of a new antiandrogen, 17a-acetoxy-6,7-epoxypregn-4-ene-3,20-dione (I). In view of the fact that the 16,17-epoxy derivatives of 4,6-pregnadiene showed high antiandrogenic activity, 1,2 it was of interest to synthesize the 6,7-epoxy analog, and evaluate it as an antiandrogen. The title compound was prepared from commercially available 17a-acetoxyprogesterone. This compound was treated with chloranil The X-ray data for crystals of the title compound were collected by graphite-monochromated Mo Ka radiation at 298(2)K. No absorption correction was applied. The structure was solved by direct methods and refined by full-matrix leastsquares with anisotropic temperature factors for the nonhydrogen atoms. The positions of all H atoms were calculated geometrically, and a riding model was used in the refinement, with C-H distances in the range of 0.93 -0.98 Å and Uiso(H) = 1.2Ueq(C). The software used to prepare material for publication was PARST97. 4 Table 1 summarizes the crystal and experimental data. The chemical and molecular structures are shown in Figs. 1 and 2 , respectively. The bond angles for non-H atoms are listed in Table 2 .
The molecule consists of three six-membered rings and one five-membered ring, all trans fused. The six-membered ring A occur between half-chair ( 1 H2) and sofa ( 1 S2); B and C occurs as an envelope ( 4 E) on C8 and sofa ( 5 S4) conformations, respectively. Ring D occurs between an envelope and half-chair conformation. Almost all of the bond lengths and angles are normal. The stereoselectivity of the title compound is as follows: C7-bH is trans to C8-aH; C8-aH is trans to C9-bCH3; C13-bCH3 is trans to C14-aH; C13-bCH3 is cis to C17-a(COCH3); and C13-b(CH3) is trans to C17a-O(CO)CH3 group. The molecules in the crystal are packed at normal van der Waals distances. There are two intermolecular C-H·O interactions: C18·O3, C21·O1, 3.030(4), 3.216(6), H18·O3, H21·O1, 2.525(3), 2.676(3)Å and C18-H18·O3, C21-H21C·O1, 112.8(2), 116.1(3)˚.
